Protein-Sparing Modified Fast — A Sardine Protocol Dossier

TL;DR

The Sardine Protocol is, mechanistically, a whole-food protein-sparing modified fast — a clinical-medicine intervention with fifty years of peer-reviewed literature, originally developed by Bistrian and Blackburn at Boston's New England Deaconess Hospital in the early 1970s ^{1 2}. PSMF supplies enough high-quality dietary protein (1.2–1.5 g/kg ideal body weight) to preserve lean tissue while restricting carbohydrate and most fat enough to sustain ketosis. Long-term outcome data ³ shows roughly 50% of clinical PSMF patients maintain ≥ 5% weight loss at 5 years — comparable to or modestly better than other intensive-weight-management interventions. The "sardine" specific contribution is recent (Hatfield 1990s, modernized via D'Agostino's lab and others) but the underlying biology is decades old. This dossier walks through what the PSMF literature does and does not establish, how a sardine-based PSMF differs from the historical liquid-formula clinical PSMF, and what protein dose to actually run for your cycle.

What we mean by PSMF

A clinical PSMF is a very-low-calorie diet (typically 600–900 kcal/day for adults under medical supervision) supplying:

• Protein: 1.2–1.5 g per kg of ideal body weight per day (~85–105 g for a 70 kg person). Originally collagen-based liquid formulas; subsequent protocols moved to milk-protein-based formulas after the early collagen-only formulas were associated with cardiac arrhythmias.
• Fat: historically minimal — most clinical PSMF protocols supplied < 20 g/day. Fat was incidental from the protein source.
• Carbohydrate: historically near-zero — < 20 g/day, primarily from non-starchy vegetables.
• Electrolyte and micronutrient supplementation: sodium, potassium, magnesium, calcium, multivitamin. Non-optional — refeeding syndrome and electrolyte derangement are real risks of any very-low-calorie protocol ⁴.

The protocol is protein-sparing because the dietary protein supply substitutes for muscle proteolysis as the source of gluconeogenic substrate. In a true water fast, the body burns through protein at roughly 50–75 g/day of muscle protein equivalent during the early days, falling as ketones progressively replace glucose in obligate-glucose tissues — the substrate biology mapped in Cahill 1970. PSMF supplies the gluconeogenic substrate from the diet, and lean mass is largely preserved.

The metabolic state is otherwise indistinguishable from a true ketogenic fast: insulin low, ketones elevated (typically 2–4 mmol/L βHB), gluconeogenesis sustaining blood glucose around 70–80 mg/dL. The substrate pattern of carbohydrate restriction, with or without total energy restriction, is well-characterized in Klein & Wolfe 1992, which shows that low-carbohydrate eating largely reproduces the substrate biology of fasting without the energy deficit.

What the evidence says (the public preview cuts here)

Clinical PSMF efficacy and safety:

Bistrian 1978 is the canonical clinical introduction of PSMF as Bistrian and Blackburn synthesized their early-1970s work into JAMA-reviewable form. Vertes 1977 reports the outpatient version showing PSMF could be run safely outside hospitalization with appropriate supervision. Contaldo 1980 examined the protein dose-response — establishing the 1.2–1.5 g/kg ideal-body-weight target that subsequent PSMF protocols largely retained.

The findings across this lineage:

• Weight loss is rapid initially. Day 1–3 weight loss is ~70% water (glycogen-bound water + sodium loss as renin-aldosterone shifts under low-carb intake). Sustained weight loss after week 1 reflects mostly fat oxidation.
• Lean mass preservation is the core claim. Bistrian and Vertes both demonstrated this clinically — PSMF protocols produced fat-mass-dominant weight loss while preserving lean mass measured by various proxies (creatinine excretion, body-impedance, anthropometric).
• Resting metabolic rate falls less than total-fast comparisons would predict. Much of the metabolic-rate decline in dieting is associated with lean-mass loss; preserving lean mass blunts the metabolic-rate adaptation.
• Adverse-event profile is favorable when the protein source is balanced and supervision is in place. The early 1970s deaths associated with collagen-only liquid formulas are historically important context but are not characteristic of subsequent PSMF protocols using balanced protein.

Long-term outcomes:

Pfoh 2020 reports 5-year follow-up data from a modern Cleveland Clinic PSMF program. The headline finding: roughly 50% of patients maintained ≥ 5% weight loss at 5 years — comparable to or modestly better than other intensive-weight-management interventions of similar magnitude. This is not a "PSMF is permanently effective" finding; it is a "PSMF performs about as well as other intensive interventions long-term, with the lean-mass-preservation advantage during the active phase." Long-term diet maintenance is hard for everyone; PSMF doesn't escape that.

Refeeding biology:

Mehanna 2008 on refeeding syndrome is a critical safety reference. Refeeding syndrome — a constellation of phosphate depletion, thiamine deficiency, fluid shifts, and cardiac dysrhythmia following resumption of carbohydrate intake after extended caloric restriction — is rare in well-managed PSMF cycles but the risk is non-zero, particularly in patients with prolonged baseline malnutrition. The protocol's published refeed guidance reflects this literature.

The ketogenic-diet outcome literature as adjacent evidence:

Sustained ketogenic eating (Volek 2009, Westman 2008, Hallberg 2018 Virta cohort) produces metabolic-syndrome biomarker improvement and durable T2D remission/reversal in clinical populations. The substrate biology overlaps with PSMF: ketosis, low insulin, fatty-acid oxidation as primary fuel, suppressed de novo lipogenesis. The differences are protein dose (often higher in PSMF), calorie level (often lower in PSMF), and intended duration (PSMF was historically continuous for weeks-to-months; sardine protocol is cycled).

Athletic context:

Phinney 1983 established that ketogenic adaptation preserves sub-maximal endurance performance in cyclists. Volek & Phinney 2016 FASTER study extended this with detailed substrate-utilization measurements in elite ultra-endurance runners, showing impressive fat-oxidation capacity in keto-adapted athletes. Moro 2016 TRF in resistance-trained men showed that intermittent-fasting patterns with maintained training do not impair maximal strength over 8 weeks. These together are the strongest evidence base for cycle-compatibility with athletic training.

The full athletic story is more nuanced — high-glycolytic-demand sports show performance impairment under ketogenic adaptation in well-controlled trials, and the interpretation requires distinguishing endurance capacity from race-pace performance. The dossier engages with this trade-off in detail in the cycle-specific section below.

Modern intermittent-fasting framings:

Anton 2018 and de Cabo & Mattson 2019 provide the contemporary "metabolic switch" framing under which short PSMF cycles can be understood as periodic engagement of the glucose-to-ketone substrate switch. The framing places monthly 5-day sardine cycles in the same conceptual family as alternate-day fasting and time-restricted feeding — periodic substrate switches with proposed cumulative benefit.